Back to news | 23rd April 2026
Recently featured in the Sunday Express, a pioneering UK stem cell therapy is offering new hope to people living with advanced heart failure, delivering life‑changing results and demonstrating strong economic value for the NHS.
Yet despite compelling clinical evidence and patient outcomes, the treatment’s next and most critical step still relies on charitable funding.
Recent UK research into stem cell therapy for advanced heart failure has delivered compelling results. Patients with no remaining treatment options have shown significant improvements in heart function, stamina and quality of life, often within weeks. Importantly, independent economic analysis also shows the treatment offers exceptional value when compared with long-term hospital care or heart transplantation.
Heart Cells Foundation funds advanced clinical trials for patients with heart failure who have exhausted all conventional treatment options. For many, this therapy has meant improved heart function, restored independence and additional years with family, outcomes that have now gained national recognition.
At Skytrail, our continued support of Heart Cells Foundation reflects a commitment to selectively backing initiatives where progress is tangible and continued support can help remove barriers to real‑world impact. In healthcare, that means supporting innovation not just at discovery, but at the point where it can genuinely change lives.
This is where responsible business involvement matters.
Heart failure remains one of the UK’s most complex and widespread health challenges. Meaningful progress depends on sustained support at critical moments, particularly where innovation is already delivering results.
Support the Next Step Forward
Heart Cells Foundation relies on charitable funding to progress this treatment through final trials and towards wider NHS adoption. Every donation helps move proven science closer to the patients who need it most.
To support their work, visit heartcellsfoundation.com/donate